(Q83929207)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22515232%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

title

Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22515232%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

main subject

phase I clinical trial

1 reference

1 reference

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22515232%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Naoki Sasahira

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22515232%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

17

Kazuhiko Koike

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22515232%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

Yousuke Nakai

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22515232%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Hiroyuki Isayama

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22515232%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Hideaki Ijichi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22515232%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Takashi Sasaki

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22515232%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Hirofumi Kogure

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22515232%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Hiroshi Yagioka

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22515232%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Koji Miyabayashi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22515232%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Suguru Mizuno

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22515232%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Keisuke Yamamoto

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22515232%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Dai Mouri

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22515232%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Natsuyo Yamamoto

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22515232%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Kenji Hirano

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22515232%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Keisuke Tateishi

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22515232%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Minoru Tada

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22515232%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

publication date

15 June 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22515232%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22515232%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

volume

103

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22515232%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22515232%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

1489-1492

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22515232%20AND%20SRC:MED&resulttype=core&format=json

Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist

29 January 2020

cites work

1 reference

12 December 2020

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

1 reference

12 December 2020

Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?

1 reference

12 December 2020

Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression

1 reference

12 December 2020

The renin-angiotensin system and malignancy

1 reference

12 December 2020

Blocking angiotensin II Type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma

1 reference

12 December 2020

Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study.

1 reference

12 December 2020

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials

1 reference

12 December 2020

Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma

1 reference

12 December 2020

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

1 reference

12 December 2020

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

1 reference

12 December 2020

Cancer. Breaching the cancer fortress

1 reference

12 December 2020

Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials

1 reference

12 December 2020

Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial

1 reference

12 December 2020

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205

1 reference

12 December 2020

Angiotensin II activates MAP kinase and NF-kappaB through angiotensin II type I receptor in human pancreatic cancer cells.

1 reference

12 December 2020

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review.

1 reference

12 December 2020

Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities.

1 reference

12 December 2020

Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials

1 reference

12 December 2020

Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer.

1 reference

12 December 2020

Does the renin-angiotensin system participate in regulation of human vasculogenesis and angiogenesis?

1 reference

12 December 2020

Microvascular angiogenesis and the renin-angiotensin system.

1 reference

12 December 2020

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

12 December 2020

Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma

1 reference

12 December 2020

Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression

1 reference

12 December 2020

Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine

1 reference

12 December 2020